查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853486

口腔给药系统市场按产品类型、药物类别、应用、最终用户和分销管道划分－2025-2032年全球预测

Buccal Drug Delivery Systems Market by Product Type, Drug Class, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，口腔给药系统市场规模将成长 51 亿美元，复合年增长率为 9.68%。

主要市场统计数据
基准年 2024 24.3亿美元
预计年份：2025年 26.7亿美元
预测年份：2032年 51亿美元
复合年增长率 (%) 9.68%

本文简要说明了口腔给药系统的现状，重点介绍了影响该领域的技术、临床和商业性驱动因素。

口腔给药系统已从最初的小众製剂发展成为靶向、快速且对患者友好的全身和局部治疗的核心方式。聚合物科学、黏膜黏附化学和器械工程的进步拓展了研发人员可用的剂型，为疼痛管理、荷尔蒙疗法、心血管治疗等领域提供了新的治疗机会。临床医生和患者都重视生物有效性原料药利用度以及绕过肝臟初始代谢（适用于那些不宜经口腔粘膜最佳递送的药物）等优点。

这些因素包括：更先进的辅料套件包，可实现精确的药物释放动力学；新型给药平台的监管核准取决于可靠的安全性数据；以及不断壮大的合约开发商和器械专家生态系统，他们能够将配方转化为可生产的产品。同时，患者的期望也转向了更方便、易于给药且能与院外医疗管道整合的治疗方法。这些趋势正在加速转化研究，增加从临床前试验进入临床评估阶段的项目数量，同时也加剧了配方方法和供应商之间的竞争。

本执行摘要概述了当前形势，指出了变革性转变，评估了不断变化的贸易政策压力带来的影响，并就市场细分、区域动态、企业行为和战略倡议建议提供了切实可行的见解。其目的是为决策者提供结构化、以证据为依据的视角，以支持其优先考虑发展投资、供应链韧性规划和相关人员参与，从而明确商业化路径。

材料进步、监管适应症和以患者为中心的设计如何从根本上改变口腔药物开发和商业化的轨迹

口腔给药领域正经历显着的变革，这主要得益于材料创新、法规的不断改进以及病患照护模式的转变。材料科学的最新突破催生了多功能聚合物的研发，这些聚合物兼具强粘附性、控制释放和舒适性，从而能够製备更薄的薄膜、更柔韧的贴剂以及具有可预测药物动力学特征的喷雾剂。同时，装置的小型化和驱动设计的改进减少了操作误差，提高了给药的一致性，从而改善了患者的用药依从性，并使其在门诊病人的应用范围更广。

法律规范正在调整以适应平台技术和组合药物，鼓励申办方更早投资于监管策略和人因工程，从而降低临床试验计画的风险。对真实世界证据和上市后监测的期望也在发生变化，要求将使用数据和安全性监测纳入产品开发计划。与监管变化同步，商业模式也不断演变。专业製剂商、契约製造和临床服务供应商之间的合作正在缩短研发週期，并降低小型创新企业的技术准入门槛。

以病人为中心的设计原则和数位化医疗的融合正变得日益重要。注重给药便利性、最大限度减少口味影响和便于隐蔽使用的配方正受到配方师和患者的青睐。与远端医疗、依从性追踪技术和数位指导工具的整合，进一步提升了口腔给药系统在以便捷性和持续给药为核心的照护路径中的价值。这些转变共同拓展了研发者的策略选择，同时也提高了产品生命週期内证据和可用性的标准。

评估2025年美国关税变化对供应链製造经济和战略采购决策的多面向影响

美国在2025年实施或提高关税将对口腔给药领域产生多方面的影响，包括采购、生产成本和策略伙伴的选择。关税压力通常会增加进口原料和特殊成分的到岸成本，迫使研发商和契约製造生产商重新评估其供应商组合。对于高价值辅料、黏合层压材料和精密製造零件等国际采购产品，提高进口关税可能会对其利润率造成压力，并促使其寻找替代供应商或将上游生产转移到关税优惠的地区。

为因应关税导致的成本上升，企业通常会加快供应链多元化和双源筹资策略，以减少对过度进口管道的依赖。这往往会导致企业增加对近岸外包和区域製造的投资，因为企业希望在地理上更紧密地协调产品开发、监管申报和商业性分销管道。此类转变可以缩短前置作业时间并控製质量，但可能需要前期投资和更长的检验期。

关税也会透过改变不同市场的相对成本结构来影响竞争动态。虽然一些赞助商可能会承受短期成本上涨，但其他赞助商可能会优先考虑成本控制，例如优化配方以去除昂贵的成分，或改进包装和物流以最大限度地降低课税价格。最后，贸易政策的变化通常会导致产业和监管机构更积极参与其中，促使他们要求澄清组合药物的关税分类，并就符合免税或优惠待遇条件的投入品寻求海关指导。总体而言，2025 年关税的影响可能会促进口腔给药生态系统内供应链韧性措施的加强、策略性回流考量以及采购流程的日益精细化。

将产品剂型、治疗层级、护理环境和分销管道与策略发展重点联繫起来，以实现全面的细分整合。

深入的市场区隔分析揭示了产品设计选择、治疗标靶和商业化管道如何相互交织，共同塑造了专案优先事项。依产品类型划分，市场可分为薄膜、凝胶、贴片、喷雾剂和片剂。薄膜可依其所用材料进一步细分为纤维素衍生物、天然聚合物和合成聚合物。纤维素衍生物通常采用羟丙基甲基纤维素和微晶纤维素来调节溶解度和黏附性。凝胶分为水凝胶和有机凝胶，二者在水合性和药物释放特性上有差异。贴片分为黏性贴剂和基质贴片，体现了应用舒适性和生产复杂性之间的权衡。片剂又可进一步分为咀嚼片、锭剂和黏膜黏附片，从而可以更好地控制黏膜接触和偏好。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 用于提高口服药物生物有效性度的黏膜黏附奈米颗粒製剂的进展
  • 利用3D列印技术客製化口服薄膜剂型，实现个人化治疗
  • 寻找渗透促进剂以优化药物经由口腔黏膜的吸收
  • 开发用于慢性疼痛管理治疗的缓释性口腔黏附凝胶
  • 利用口腔贴片中的无线感测器进行即时病患遵从性监测
  • 透过引入环状胜肽载体，提高了口腔内疫苗递送的稳定性。
  • 影响新型口服药物递送系统核准的监管挑战和协调工作
  • 利用口腔递送胜肽类和小分子药物治疗慢性疾病

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的口腔给药系统市场

  • 电影
    • 纤维素衍生物
      • 羟丙基甲基纤维素
      • 微晶纤维素
    • 天然聚合物
    • 合成聚合物
  • 凝胶
    • 水凝胶
    • 有机凝胶
  • 修补
    • 黏性贴片
    • 矩阵补丁
  • 喷
    • 多驱动
    • 单次驱动
  • 药片
    • 咀嚼片
    • 锭剂
    • 黏膜黏附片

9. 按药物类别分類的口腔给药系统市场

  • 止痛药
    • Buprenornhine
    • Fentanyl
  • 心血管系统
    • 硝酸甘油
  • 中枢神经系统
  • 荷尔蒙
    • 雌二醇
    • 睪固酮

第十章 按应用分類的口腔给药系统市场

  • 心血管治疗
  • 荷尔蒙疗法
  • 疼痛管理
  • 精神科护理

第十一章 依最终使用者分類的口腔给药系统市场

  • 诊所
  • 居家医疗
  • 医院

第十二章 按分销管道分類的口腔给药系统市场

  • 医院药房
  • 网路药房
  • 零售药房

13. 按地区分類的口腔给药系统市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 口腔给药系统市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国口腔给药系统市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GlaxoSmithKline plc
    • Novartis AG
    • Johnson & Johnson
    • Pfizer Inc.
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Bausch Health Companies Inc.
    • BioDelivery Sciences International, Inc.
    • Roche Holding AG
Product Code: MRR-3A2E844FF422

The Buccal Drug Delivery Systems Market is projected to grow by USD 5.10 billion at a CAGR of 9.68% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.43 billion
Estimated Year [2025] USD 2.67 billion
Forecast Year [2032] USD 5.10 billion
CAGR (%) 9.68%

A concise orientation to the current state of buccal drug delivery systems capturing technological, clinical, and commercial drivers reshaping the field

Buccal drug delivery systems have evolved from niche formulations to a core modality for targeted, rapid and patient-friendly systemic and local therapies. Advances in polymer science, mucoadhesive chemistries and device engineering have expanded the palette of dosage forms available to developers, enabling new therapeutic opportunities across pain management, hormonal therapies and cardiovascular care. Clinicians and patients alike appreciate buccal routes for their noninvasive administration, improved bioavailability for suitable APIs, and the ability to bypass first-pass hepatic metabolism for drugs where oral delivery is suboptimal.

The clinical and commercial interest in buccal delivery is being shaped by converging forces: more sophisticated excipient toolkits that allow precise release kinetics, regulatory acceptance of novel delivery platforms contingent on robust safety data, and a growing ecosystem of contract developers and device specialists able to translate formulations into manufacturable products. Concurrently, patient expectations are shifting toward discreet, easy-to-administer therapies that integrate with care pathways outside the hospital. These dynamics are accelerating translational activity and increasing the number of programs progressing from preclinical demonstration to clinical evaluation, while also intensifying competition among formulation approaches and supplier partnerships.

This executive summary frames the current state of the landscape, highlights transformational shifts, assesses the implications of evolving trade policy pressures, and provides pragmatic insights on segmentation, regional dynamics, corporate behavior and recommended strategic moves. The objective is to equip decision-makers with a structured, evidence-based view that supports prioritization of development investments, supply chain resiliency planning and engagement with regulatory stakeholders to clear pathways for commercialization.

How material advances regulatory adaptation and patient-centric design are fundamentally changing development and commercial pathways for buccal therapies

The landscape for buccal drug delivery is undergoing transformative shifts driven by material innovation, regulatory evolution, and changing patient care models. Recent material science breakthroughs have led to multifunctional polymers that combine strong mucoadhesion with controlled release and patient comfort, enabling thinner films, more flexible patches and spray formulations that achieve predictable pharmacokinetic profiles. At the same time, device miniaturization and actuation design have reduced user error and increased dosing consistency, which enhances adherence and supports broader outpatient use.

Regulatory frameworks are adapting to accommodate platform technologies and combination products, prompting sponsors to invest earlier in regulatory strategy and human factors engineering to de-risk clinical programs. Real-world evidence and post-market surveillance expectations are also shifting, requiring integration of usage data and safety monitoring into product development plans. Parallel to regulatory change, commercial models are evolving: partnerships between specialty formulation houses, contract manufacturers and clinical service providers are shortening development timelines and lowering technical barriers to entry for smaller innovators.

Patient-centric design principles and digital health linkages are increasingly influential. Formulations that prioritize ease of administration, minimal taste impact and discreet handling are gaining traction among prescribers and patients. Integration with telemedicine, adherence-tracking technologies and digital instructional aids further amplifies the perceived value of buccal delivery systems in care pathways where convenience and consistent dosing are paramount. Together, these shifts are expanding the strategic options for developers while raising the bar for evidence and usability across product lifecycles.

Evaluating the multifaceted consequences of United States tariff changes in 2025 on supply chains manufacturing economics and strategic sourcing decisions

The imposition or increase of tariffs by the United States in 2025 would have a multi-dimensional effect on the buccal drug delivery sector, influencing sourcing, manufacturing economics and strategic partner selection. Tariff pressure typically increases the landed cost of imported raw materials and specialized components, which forces developers and contract manufacturers to reassess supplier portfolios. For high-value excipients, adhesive laminates, and precision manufacturing components that are sourced internationally, increased import duties would create margin pressure and could incentivize qualification of alternate suppliers or relocation of upstream production to tariff-favored jurisdictions.

In response to tariff-driven cost increases, companies often accelerate supply chain diversification and dual-sourcing strategies to mitigate exposure to import-heavy routes. This tends to elevate nearshoring and regional manufacturing investment as sponsors seek closer geographic alignment between development, regulatory submission, and commercial distribution channels. Such shifts can improve lead times and control over quality but may require upfront capital and extended validation timelines.

Tariffs also influence competitive dynamics by altering relative cost structures across markets. Some sponsors may absorb short-term cost increases, while others could prioritize cost-containment via formulation optimization to reduce expensive components, or by altering packaging and logistics to minimize dutiable value. Finally, trade policy shifts typically heighten engagement between industry and regulators, prompting requests for clarifications on tariff classifications for combination products and for customs guidance on inputs that are eligible for exemptions or preferential treatment. Overall, tariff effects in 2025 would act as a catalyst for supply chain resilience measures, strategic reshoring considerations and intensified procurement sophistication within the buccal delivery ecosystem.

A comprehensive segmentation synthesis linking product formulations therapeutic classes care settings and distribution channels to strategic development priorities

Insightful segmentation analysis underscores how product design choices, therapeutic targets and commercialization pathways intersect to shape program priorities. Based on product type, the field encompasses films, gels, patches, sprays, and tablets, where films are further differentiated by cellulose derivatives, natural polymers, and synthetic polymers; within cellulose derivatives, formulations commonly leverage hydroxypropyl methylcellulose and microcrystalline cellulose to tune dissolution and adhesion. Gels bifurcate into hydrogels and organogels that offer distinct hydration and drug-release profiles, while patches are manufactured as either adhesive patches or matrix patches reflecting trade-offs between application comfort and manufacturing complexity. Spray formats are categorized by multi-actuation and single-actuation systems, each supporting different dosing strategies, and tablet options span chewable tablets, lozenges, and mucoadhesive tablets that deliver controlled mucosal contact and palatability.

Based on drug class, developers are targeting analgesics, cardiovascular agents, central nervous system therapies, and hormones. Analgesic programs commonly explore buprenorphine and fentanyl derivatives for rapid-onset pain management and opioid-dependence therapies, while cardiovascular efforts frequently evaluate nitroglycerin for acute angina relief via transmucosal absorption. Hormone-focused delivery studies emphasize estradiol and testosterone for hormone replacement strategies that benefit from mucosal uptake and dose precision.

Based on application, product development is organized around cardiovascular treatment, hormone therapy, pain management, and psychiatry, each application presenting unique pharmacokinetic, safety and usability constraints that inform formulation choice and device architecture. Based on end user, the market must account for clinics, home care, and hospitals, with each setting imposing specific requirements for administration training, packaging robustness and storage. Based on distribution channel, commercialization strategies are tailored to hospital pharmacy, online pharmacy, and retail pharmacy channels, which determine labeling, patient education needs and fulfillment logistics. Together, these segmentation dimensions provide a matrix to prioritize R&D investments and align clinical evidence generation with intended use environments.

Regional dynamics and regulatory variations across the Americas Europe Middle East & Africa and Asia-Pacific that shape market entry and manufacturing strategies

Regional dynamics are central to strategic planning as regulatory frameworks, manufacturing ecosystems and payer behaviors vary significantly across geographies. In the Americas, regulatory emphasis on robust clinical evidence and well-defined labeling for transmucosal products coexists with a mature contract manufacturing sector and an appetite for outpatient-friendly formulations. This region favors rapid deployment of products that demonstrate clear benefits in adherence or pharmacokinetics, and it supports innovative reimbursement pathways for therapies that reduce acute care utilization.

In Europe, Middle East & Africa, regulatory heterogeneity necessitates targeted pathways for approval and post-market surveillance. Manufacturers must navigate regional differences in pharmacovigilance requirements and device classification rules, while leveraging strong CDMO networks in parts of Western Europe for pilot-scale and commercial manufacturing. Market access in this region is increasingly driven by health technology assessment mechanisms and cost-effectiveness arguments, particularly for therapies that displace more resource-intensive interventions.

In Asia-Pacific, dynamic growth in clinical research capacity and investments in local manufacturing create opportunities for scale and cost-effective production. Regulatory authorities in several markets are modernizing frameworks for combination products, and the rapidly expanding middle-class patient population is driving demand for convenient, outpatient-friendly drug delivery options. Across all regions, regionalization of supply chains and regulatory intelligence functions is becoming a best practice to reduce time-to-market and to optimize commercial rollout sequencing based on payer receptivity and clinical adoption patterns.

How specialist innovators strategic partnerships and contract manufacturers are shaping competitive advantage and value creation in buccal delivery

Corporate behavior within the buccal delivery ecosystem is characterized by a blend of specialist innovators, strategic partnerships, and an active outsourcing market for development and manufacturing. Companies focused on novel excipients and mucoadhesive chemistries invest in proprietary platforms that can be licensed to originators or biotechs seeking differentiated release profiles and tactile properties. Contract development and manufacturing organizations play a pivotal role in translating lab-scale prototypes into commercial processes, often providing end-to-end services that reduce capital requirements for product sponsors.

Strategic collaborations between formulation houses, device engineers and clinical services firms are increasingly prevalent, accelerating clinical development timelines and facilitating the integration of human factors and usability testing early in the design cycle. Corporate strategies also emphasize intellectual property protection around both formulation and delivery systems, balanced with selective licensing to expand geographic reach or therapeutic scope. In parallel, smaller specialist firms tend to focus on high-value niches such as opioid substitution therapies or hormone replacement products where buccal administration provides distinct clinical advantages.

Investors and corporate development teams are prioritizing assets that demonstrate clear differentiation in user experience, manufacturability and regulatory readiness. There is also growing attention to sustainability in packaging and supply chain transparency, as procurement teams place higher value on suppliers that can demonstrate environmental and social governance practices. Together, these trends highlight a competitive environment where technical excellence, regulatory foresight and strategic partnering determine which companies can scale and sustain commercial success.

Practical strategic actions for developers manufacturers and investors to de-risk programs accelerate timelines and maximize commercial uptake in buccal therapies

To navigate the opportunities and risks in buccal drug delivery, industry leaders should adopt a multi-pronged strategy that aligns technical, regulatory and commercial priorities. First, prioritize cross-functional regulatory planning early in development to define the combination product pathway, human factors requirements and post-market surveillance obligations; this reduces downstream surprises and optimizes trial design. In parallel, invest in formulation robustness and manufacturability assessments to ensure that chosen excipients and device interfaces scale reliably and meet quality-by-design expectations.

Second, build resilient supply chains through supplier qualification, dual-sourcing and regional manufacturing options to mitigate the impact of trade policy shifts and logistics disruptions. Engaging contract manufacturing partners with proven experience in mucoadhesive systems can compress development timelines while preserving quality control. Third, embed patient-centered design criteria in product development, including palatability, ease of administration and adherence support, and validate these attributes through early human factors testing and real-world pilot studies to inform labeling and training materials.

Fourth, pursue strategic collaborations and licensing arrangements to access complementary capabilities such as advanced polymers or device actuation technology rather than attempting to internalize all competencies. Finally, incorporate sustainability and traceability into procurement and packaging decisions to meet growing payer and institutional buyer expectations and to reduce long-term operational risk. These actions together create a pragmatic roadmap to de-risk development, accelerate market entry and enhance commercial uptake.

A robust mixed-methods research approach combining primary expert interviews and secondary technical regulatory review to ensure actionable and validated insights

This analysis synthesizes primary qualitative engagement with clinical experts formulation scientists regulatory specialists and supply chain managers, combined with structured secondary research into published regulatory guidance technical literature and company disclosures. Primary inputs included targeted interviews to surface real-world operational constraints and human factors considerations that are often absent from public filings, while secondary sources provided context on material science trends and regulatory precedent for combination products.

The research methodology prioritized triangulation across data streams to validate conclusions. Technical claims regarding polymer behavior and device performance were cross-checked with peer-reviewed literature and vendor technical dossiers. Regulatory pathway observations were referenced to publicly available guidance documents and precedent submissions, and policy-related inferences about trade impacts were grounded in documented tariff mechanisms and historical market responses. Where appropriate, anonymized practitioner perspectives were used to illustrate operational realities without disclosing proprietary information.

Analytical rigor was maintained through a systematic framework that mapped segmentation, regional dynamics and strategic levers against development and commercial outcomes. Limitations of the study are acknowledged where proprietary data or emerging clinical outcomes remain confidential, and recommendations emphasize actions that can be implemented with standard due diligence. Overall, the methodology balances depth of technical insight with practical relevance for commercial decision-making.

A concise synthesis of strategic imperatives and practical takeaways to convert buccal delivery innovation into commercial and clinical success

In conclusion, buccal drug delivery systems occupy an increasingly important role within the pharmaceutical toolkit, offering distinct clinical and commercial advantages where rapid onset, avoidance of first-pass metabolism and outpatient-friendly administration are priorities. The interplay between polymer innovation, device engineering and regulatory strategy has broadened feasible therapeutic applications, while patient-centric design and digital adjuncts enhance real-world value. The sector is responding to external pressures such as trade policy and supply chain risk by accelerating supplier diversification and regional manufacturing alignment, which in turn influences program economics and go-to-market sequencing.

Decision-makers should focus on aligning formulation choices with clear clinical articulation of benefit, investing in manufacturability and regulatory readiness early, and leveraging partnerships to access specialized competencies. Regional nuance in regulatory and payer environments necessitates tailored market-entry strategies, and companies that demonstrate both technical excellence and operational resilience are best positioned to win. The recommendations presented herein provide a pragmatic blueprint to prioritize investments and accelerate commercialization while maintaining compliance and protecting quality.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancement in mucoadhesive nanoparticle formulations for enhanced buccal drug bioavailability
  • 5.2. Application of 3D printing technologies to customize buccal film dosage forms for personalized therapy
  • 5.3. Exploration of permeation enhancers to optimize drug absorption through buccal mucosa membranes
  • 5.4. Development of sustained-release buccal adhesive gels for chronic pain management therapies
  • 5.5. Use of wireless sensors in buccal patches for real-time monitoring of patient drug compliance
  • 5.6. Implementation of cyclic peptide-based carriers to improve stability of buccal vaccine delivery
  • 5.7. Regulatory challenges and harmonization efforts impacting novel buccal drug delivery approvals
  • 5.8. Growth in chronic disease management using transbuccal delivery of peptide and small molecule drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Buccal Drug Delivery Systems Market, by Product Type

  • 8.1. Films
    • 8.1.1. Cellulose Derivatives
      • 8.1.1.1. Hydroxypropyl Methylcellulose
      • 8.1.1.2. Microcrystalline Cellulose
    • 8.1.2. Natural Polymers
    • 8.1.3. Synthetic Polymers
  • 8.2. Gels
    • 8.2.1. Hydrogels
    • 8.2.2. Organogels
  • 8.3. Patches
    • 8.3.1. Adhesive Patches
    • 8.3.2. Matrix Patches
  • 8.4. Sprays
    • 8.4.1. Multi Actuation
    • 8.4.2. Single Actuation
  • 8.5. Tablets
    • 8.5.1. Chewable Tablets
    • 8.5.2. Lozenges
    • 8.5.3. Mucoadhesive Tablets

9. Buccal Drug Delivery Systems Market, by Drug Class

  • 9.1. Analgesics
    • 9.1.1. Buprenorphine
    • 9.1.2. Fentanyl
  • 9.2. Cardiovascular
    • 9.2.1. Nitroglycerin
  • 9.3. Central Nervous System
  • 9.4. Hormones
    • 9.4.1. Estradiol
    • 9.4.2. Testosterone

10. Buccal Drug Delivery Systems Market, by Application

  • 10.1. Cardiovascular Treatment
  • 10.2. Hormone Therapy
  • 10.3. Pain Management
  • 10.4. Psychiatry

11. Buccal Drug Delivery Systems Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Buccal Drug Delivery Systems Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Buccal Drug Delivery Systems Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Buccal Drug Delivery Systems Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Buccal Drug Delivery Systems Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. Novartis AG
    • 16.3.3. Johnson & Johnson
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Bayer AG
    • 16.3.6. Teva Pharmaceutical Industries Ltd.
    • 16.3.7. Viatris Inc.
    • 16.3.8. Bausch Health Companies Inc.
    • 16.3.9. BioDelivery Sciences International, Inc.
    • 16.3.10. Roche Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BUCCAL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BUCCAL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BUCCAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2024